Rare-disease specialty pharma selling Wakix for narcolepsy and building a broader sleep-disorder pipeline.
Rare-disease specialty pharma selling Wakix for narcolepsy and building a broader sleep-disorder pipeline.
Nearly all revenue comes from Wakix, sold through a small number of specialty pharmacies to patients whose doctors prescribe it, and reported net of rebates and discounts. Pitolisant came through a licence from Bioprojet, a French drug developer, to which royalties are paid.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and a first-in-class mechanism protect Wakix from direct generic competition.
Headquarters: Plymouth Meeting, Pennsylvania, US · Founded: 2017 · Employees: 293
Size Harmony Biosciences (HRMY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.94B, the 1790th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.11 on 18 Nov 2026.
Performance Over six months the shares gained 5.5%, against -5.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 19.8% over the last twelve months (peer median +8.7%); the operating margin is 22.2% (peer median 17.9%).
Valuation It trades at 8.6× forward earnings against a peer median of 22.8× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -51 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 22.8 points above its cost of capital (9.6% WACC).
Short interest Short interest is 11.3% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $989M | $868M | $715M | $582M | $438M |
| Revenue growth | — | +22% | +23% | +33% | — |
| Gross profit | $709M | $646M | $534M | $437M | $331M |
| EBITDA | $245M | $234M | $215M | $216M | $144M |
| Net income | $179M | $159M | $145M | $129M | $181M |
| Free cash flow | $323M | $348M | $219M | $219M | $144M |
| Capital expenditure | $19.4M | $19.6M | $27.7M | $312,000 | $40.2M |
| Total debt | $233M | $235M | $233M | $196M | $193M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Harmony Biosciences HRMY | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Axsome Therapeutics AXSM | $7.05B | -42% | +54% | -19% | 77.1× | n/a |
| Alkermes Public ALKS | $7.87B | +27% | +15% | 5% | n/a | 32.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | HRMY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.4% | +2.7% | 2nd lowest of 21 |
| 6-month return | +5.5% | -5.5% | 9th highest of 21 |
| Distance from 52-week high | -23.9% | -28.8% | 9th highest of 21 |
| Revenue growth (TTM) | +19.8% | +8.7% | 4th highest of 20 |
| Operating margin | 22.2% | 17.9% | 8th highest of 20 |
| Forward P/E | 8.6× | 22.8× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -10.5% | 3.4% | least demanding of 13 |
| Growth delivered (Del g) | +40.3% | +9.9% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -50.8 pp | -6.3 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | +22.8 pp | +0.1 pp | 3rd highest of 20 |
| EV / EBITDA | 5.7× | 17.8× | cheapest of 10 |
| Net debt / EBITDA | -2.2× | 1.4× | 2nd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |